Dow Pharmaceutical Sciences   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Petaluma CA United States (1897)
Status: Acquired by Bausch Health Companies (2008)

Organization Overview

First Clinical Trial
2006
NCT00664248
First Marketed Drug
1954
polymyxin b sulfate (poly-rx)
First NDA Approval
2014
efinaconazole (jublia)
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Dow Hickam Pharmaceuticals | DOW PHARM